Centre Hospitalier de l'Université de Montréal, Quebec, Canada.
Semin Oncol. 2010 Jun;37 Suppl 1:S38-44. doi: 10.1053/j.seminoncol.2010.06.001.
Approximately 30% of patients with renal cell carcinoma (RCC) and 40% of patients with bladder cancer develop bone metastases that can disrupt normal bone homeostasis and place patients at risk for potentially life-limiting skeletal-related events (SREs). In the absence of bone-directed therapies, patients with RCC may experience up to four SREs per year. In patients with bone metastases from RCC or bladder cancer, zoledronic acid (ZOL) significantly reduced the risk of SREs compared with placebo. In addition to its bone-protective effects, preclinical and early clinical evidence indicates that ZOL prevents tumor progression. For example, retrospective subset analysis in patients with RCC indicated that ZOL extended time to disease progression and demonstrated a trend toward improved overall survival compared with placebo. Additionally, a study in patients with bone metastases from bladder cancer demonstrated that ZOL improved 1-year overall survival compared with placebo. Bone metastases place a heavy burden on patients with RCC or bladder cancer, and early, continuous treatment with ZOL may provide anticancer benefits in addition to important patient quality of life.
约 30%的肾细胞癌（RCC）患者和 40%的膀胱癌患者会发生骨转移，这可能破坏正常的骨稳态，并使患者面临潜在的危及生命的骨骼相关事件（SREs）的风险。在没有针对骨骼的治疗方法的情况下，RCC 患者每年可能会经历多达 4 次 SREs。对于 RCC 或膀胱癌骨转移患者，唑来膦酸（ZOL）与安慰剂相比，显著降低了 SREs 的风险。除了具有骨保护作用外，临床前和早期临床证据表明，ZOL 可预防肿瘤进展。例如，在 RCC 患者的回顾性亚组分析中，ZOL 延长了疾病进展时间，与安慰剂相比，总生存趋势有所改善。此外，在膀胱癌骨转移患者中进行的一项研究表明，ZOL 与安慰剂相比，提高了 1 年总生存率。骨转移给 RCC 或膀胱癌患者带来了沉重的负担，早期持续使用 ZOL 可能除了为患者带来重要的生活质量改善外，还能带来抗癌益处。
